MacroGenics reported $-30.2M in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
AbbVie USD 5.37B 1.85B Dec/2025
Amgen USD 5.14B 775M Dec/2025
AstraZeneca USD 5.67B 1.29B Mar/2026
Biogen USD 649.7M 76.5M Mar/2026
Bristol-Myers Squibb USD 2.88B 1.36B Dec/2025
Daiichi Sankyo JPY 101.6B 22.81B Mar/2025
Eli Lilly USD 12.14B 4.26B Dec/2025
Genmab DKK 186M 291M Dec/2025
Geron USD -21.29M 11.82M Dec/2025
Gilead Sciences USD 3.02B 1.01B Dec/2025
J&J USD 8.27B 1.08B Mar/2026
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
MacroGenics USD -30.2M 52.15M Mar/2026
Merck USD 6.3B 2.09B Dec/2025
Pfizer USD 5.99B 5.23B Mar/2026
Puma Biotechnology USD 729K 11.36M Jun/2024
Regeneron Pharmaceuticals USD 1.2B 718.4M Dec/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Xencor USD -51.05M 55.28M Dec/2025